Lee Young Sub, Lee Sung Hak, Choi Yeong Jin, Jung Eun Sun
Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Cancer Res Ther. 2014 Jul-Sep;10(3):763-6. doi: 10.4103/0973-1482.136030.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs), such as imatinibmesylate, have been used for the adjuvant treatment of KIT-positive GISTs. Several pathologic changes after imatinib treatment of metastatic GIST including tumor necrosis, myxohyaline or sclerohyalinestroma, proliferative index decline, a varying degree of hemorrhage, edema, and cystic change have been reported in previous studies. More specifically, cystic changes after imatinib treatment were mainly induced by necrosis, hemorrhage, and degeneration. Until now, there have been no reports of cystic changes due to a dilated bile duct entrapped by a totally regressed tumor. We report a case of a 61-year-old man who was diagnosed with high-risk GIST of the stomach complicated by hepatic metastasis and who had such a unique pathologic changes with imatinib treatment.
胃肠道间质瘤（GIST）是胃肠道最常见的间质性肿瘤。酪氨酸激酶抑制剂（TKIs），如甲磺酸伊马替尼，已被用于KIT阳性GIST的辅助治疗。先前的研究报道了伊马替尼治疗转移性GIST后的几种病理变化，包括肿瘤坏死、黏液透明或硬化透明基质、增殖指数下降、不同程度的出血、水肿和囊性变。更具体地说，伊马替尼治疗后的囊性变主要由坏死、出血和变性引起。到目前为止，尚无因完全消退的肿瘤包绕扩张胆管导致囊性变的报道。我们报告一例61岁男性患者，他被诊断为胃高危GIST并伴有肝转移，接受伊马替尼治疗后出现了这种独特的病理变化。
